Kestra Private Wealth Services LLC Buys 5,767 Shares of Boston Scientific Co. (NYSE:BSX)

Kestra Private Wealth Services LLC increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 21.1% during the 4th quarter, Holdings Channel reports. The fund owned 33,153 shares of the medical equipment provider’s stock after buying an additional 5,767 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Boston Scientific were worth $2,961,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Compagnie Lombard Odier SCmA grew its holdings in shares of Boston Scientific by 280.4% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 3,100 shares of the medical equipment provider’s stock valued at $260,000 after buying an additional 2,285 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its stake in Boston Scientific by 32.4% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,786 shares of the medical equipment provider’s stock valued at $317,000 after acquiring an additional 927 shares during the period. Paladin Wealth LLC bought a new stake in shares of Boston Scientific in the third quarter worth about $586,000. ORG Wealth Partners LLC acquired a new stake in shares of Boston Scientific during the third quarter worth about $89,000. Finally, Grove Bank & Trust lifted its holdings in shares of Boston Scientific by 12.9% during the 3rd quarter. Grove Bank & Trust now owns 2,801 shares of the medical equipment provider’s stock valued at $235,000 after purchasing an additional 320 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on BSX. JPMorgan Chase & Co. increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Citigroup raised their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Friday, January 10th. Bank of America lifted their price target on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Finally, Morgan Stanley upped their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $107.39.

Boston Scientific Stock Up 0.9 %

Boston Scientific stock opened at $106.15 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The company’s 50-day moving average is $94.88 and its 200-day moving average is $87.28. The firm has a market capitalization of $156.44 billion, a PE ratio of 84.92, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $64.54 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Sell-side analysts anticipate that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now directly owns 29,308 shares in the company, valued at $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company’s stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,830 shares of company stock worth $5,149,969. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.